Mineralys Therapeutics (MLYS) EPS (Basic) (2022 - 2026)

Mineralys Therapeutics has reported EPS (Basic) for 5 years, with the latest figure at -$0.55 in Q1 2026.

• Quarterly EPS (Basic) rose 34.53% year-over-year to -$0.55 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.84 (up 27.52% YoY) and the FY2025 annual result came in at -$4.68, up 16.51% from the prior year.
• EPS (Basic) rose to -$0.55 in Q1 2026 per MLYS's latest filing, from -$2.73 in the prior quarter.
• Over five years, EPS (Basic) peaked at -$0.4 in Q2 2023 and troughed at -$2.73 in Q4 2025.
• A 5-year average of -$1.15 and a median of -$0.84 in 2025 frame the typical range for EPS (Basic).
• The sharpest annual moves came in 2023 and 2024: EPS (Basic) jumped 68.52% in 2023, then tumbled 243.69% in 2024.
• Over 5 years, EPS (Basic) stood at -$1.97 in 2022, then jumped by 59.97% to -$0.79 in 2023, then slumped by 243.69% to -$2.71 in 2024, then slipped by 0.57% to -$2.73 in 2025, then jumped by 79.94% to -$0.55 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.55, -$2.73, and -$0.58 for Q1 2026, Q4 2025, and Q3 2025 respectively.